Key result
Transcriptome data analysis across primary cardiomyopathies revealed significant perturbations in arachidonic acid metabolism, with the PLA2G2A gene interacting with fibroblast markers to potentially influence fibrosis.
Why the study?
Metabolic profile correlation across different primary cardiomyopathies remains poorly understood, despite continuous myocardial stress and cardiomyopathies driving metabolic impairment that advances heart failure pathogenesis.
AA metabolism perturbations may influence cardiomyopathy fibrosis; leaves open targeted therapies pending prospective validation.
Introduction Cardiomyopathies are complex heart diseases with significant prevalence around the world. Among these, primary forms are the major contributors to heart failure and sudden cardiac death. As a high-energy demanding engine, the heart utilizes fatty acids, glucose, amino acid, lactate and ketone bodies for energy to meet its requirement. However, continuous myocardial stress and cardiomyopathies drive towards metabolic impairment that advances heart failure (HF) pathogenesis. So far, metabolic profile correlation across different cardiomyopathies remains poorly understood. Methods In this study, we systematically explore metabolic differences amongst primary cardiomyopathies. By assessing the metabolic gene expression of all primary cardiomyopathies, we highlight the significantly shared and distinct metabolic pathways that may represent specialized adaptations to unique cellular demands. We utilized publicly available RNA-seq datasets to profile global changes in the above diseases (| log2FC | ≥ 0.28 and BH adjusted p-val 0.1) and performed gene set analysis (GSA) using the PAGE statistics on KEGG pathways. Results Our analysis demonstrates that genes in arachidonic acid metabolism (AA) are significantly perturbed across cardiomyopathies. In particular, the arachidonic acid metabolism gene PLA2G2A interacts with fibroblast marker genes and can potentially influence fibrosis during cardiomyopathy. Conclusion The profound significance of AA metabolism within the cardiovascular system renders it a key player in modulating the phenotypes of cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Chauhan et al. (2023) studied Primary cardiomyopathies (ACM, DCM, HCM, RCM). Primary cardiomyopathies vs. Non-failing donor heart samples was evaluated on Differentially expressed genes and perturbed metabolic pathways. Transcriptome data analysis across primary cardiomyopathies revealed significant perturbations in arachidonic acid metabolism, with the PLA2G2A gene interacting with fibroblast markers to potentially influence fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: